Homepage
     About us
     Wholesale ph.
     Research
     Contact
 

Our way of work Farmacija program Research
 
 
News
Marketing authorisation of Enkorten in Bosnia and Herzegovina
Enkorten is registered in February 2010 in Bosnia and Herzegovina with a registration number 04-07.1-1655-1/09 issued from Drug Agency of Bosnia and Herzegovina.
WCN 2009
During the World Congress of Neurology (Bangkok, 24-30 October) Farmacija d.o.o. presented the results of phase III clinical study of Enkorten's efficacy in three different abstracts. Read more...
Safety Profile
Safety profile of Enkorten was presented during the III Congress of neurology nurses and techicians in Opatija from 22 to 25 of April 2009. Read more...
Clinical Phase III
In December 2008 a complex statistical analysis of clinical phase III results was completed. Read more...
Presentation of the clinical phase II
Clinical phase II results of efficacy of Enkorten were presented during the 12 EFNS Congress in Spain in 2008.  
Read more...
 
     Salivarni Proteini


Farmacija created a library of compounds based on repetitive sequences (motifs) of the salivary praline rich proteins, mucin and collagen by means of the software SCAN and derived five structural peptide formulas (SALIVAR, SALIVAL, SALIVAN, MUCOSEPT and PROCOL). Peptide sequences are designed for the modulation of cell and tissue growth, division and differentiation.
Various sequences are under preclinical investigation.

Patent: Farmacija has the exclusive world-wide licence to all intellectual property related to peptides.



PARTNERSHIP OPPORTUNITIES

     Farmacija offers strategic opportunities for partners:

   - Joint-venture partnerships
   - In-licensing
   - Out-licensing
   - Alliances
   - Wholesale and distribution

 

 

  
 
   
Homepage About us Wholesale pharmacy Contact